Advances in anti-fungal therapies

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)


Anti-fungal therapies remain sub-optimal, and resistant pathogens are increasing. New therapies are desperately needed, especially options that are less toxic than most of the currently available selection. In this review, I will discuss anti-fungal therapies that are in at least phase I human trials. These include VT-1161 and VT-1598, modified azoles with a tetrazole metal-binding group; the echinocandin rezafugin; the novel β-1,3-d-glucan synthase inhibitor ibrexafungerp; fosmanogepix, a novel anti-fungal targeting Gwt1; the arylamidine T-2307; the dihydroorotate inhibitor olorofim; and the cyclic hexapeptide ASP2397. The available data including spectrum of activity, toxicity and stage of clinical development will be discussed for each of these so clinicians are aware of promising anti-fungal agents with a strong likelihood of clinical availability in the next 5–7 years.

Original languageEnglish
Pages (from-to)665-672
Number of pages8
Issue number5
Publication statusPublished - Oct 2021


Dive into the research topics of 'Advances in anti-fungal therapies'. Together they form a unique fingerprint.

Cite this